Ra Capital Management, L.P. Sells 151,803 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 151,803 shares of the stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $29.45, for a total transaction of $4,470,598.35. Following the completion of the sale, the director directly owned 57,920 shares in the company, valued at approximately $1,705,744. The trade was a 72.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total transaction of $1,569,139.65.

Vor Biopharma Stock Down 0.2%

NASDAQ VOR opened at $29.00 on Friday. The business has a 50 day moving average price of $36.55. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The stock has a market cap of $198.77 million, a PE ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Money Concepts Capital Corp lifted its holdings in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in Vor Biopharma in the second quarter worth $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter valued at about $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma during the first quarter valued at about $140,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Zacks Research downgraded Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Wall Street Zen lowered shares of Vor Biopharma to a “strong sell” rating in a research report on Saturday, June 28th. Stifel Nicolaus raised shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Wednesday, September 24th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.